852 related articles for article (PubMed ID: 15259903)
1. Psychosocial determinants of adherence to highly active antiretroviral therapy among injection drug users in Vancouver.
Kerr T; Palepu A; Barness G; Walsh J; Hogg R; Montaner J; Tyndall M; Wood E
Antivir Ther; 2004 Jun; 9(3):407-14. PubMed ID: 15259903
[TBL] [Abstract][Full Text] [Related]
2. Determinants of HAART discontinuation among injection drug users.
Kerr T; Marshall A; Walsh J; Palepu A; Tyndall M; Montaner J; Hogg R; Wood E
AIDS Care; 2005 Jul; 17(5):539-49. PubMed ID: 16036240
[TBL] [Abstract][Full Text] [Related]
3. Antiretroviral adherence and HIV treatment outcomes among HIV/HCV co-infected injection drug users: the role of methadone maintenance therapy.
Palepu A; Tyndall MW; Joy R; Kerr T; Wood E; Press N; Hogg RS; Montaner JS
Drug Alcohol Depend; 2006 Sep; 84(2):188-94. PubMed ID: 16542797
[TBL] [Abstract][Full Text] [Related]
4. Initiating highly active antiretroviral therapy and continuity of HIV care: the impact of incarceration and prison release on adherence and HIV treatment outcomes.
Palepu A; Tyndall MW; Chan K; Wood E; Montaner JS; Hogg RS
Antivir Ther; 2004 Oct; 9(5):713-9. PubMed ID: 15535408
[TBL] [Abstract][Full Text] [Related]
5. Depression and clinical progression in HIV-infected drug users treated with highly active antiretroviral therapy.
Bouhnik AD; Préau M; Vincent E; Carrieri MP; Gallais H; Lepeu G; Gastaut JA; Moatti JP; Spire B;
Antivir Ther; 2005; 10(1):53-61. PubMed ID: 15751763
[TBL] [Abstract][Full Text] [Related]
6. Determinants of adherence to highly active antiretroviral therapy among HIV-1-infected patients in Côte d'Ivoire.
Diabaté S; Alary M; Koffi CK
AIDS; 2007 Aug; 21(13):1799-803. PubMed ID: 17690579
[TBL] [Abstract][Full Text] [Related]
7. Poor adherence to HIV monitoring and treatment guidelines for HIV-infected injection drug users.
Wood E; Kerr T; Zhang R; Guillemi S; Palepu A; Hogg RS; Montaner JS
HIV Med; 2008 Aug; 9(7):503-7. PubMed ID: 18484977
[TBL] [Abstract][Full Text] [Related]
8. Increase in sexual risk behavior associated with immunologic response to highly active antiretroviral therapy among HIV-infected injection drug users.
Tun W; Gange SJ; Vlahov D; Strathdee SA; Celentano DD
Clin Infect Dis; 2004 Apr; 38(8):1167-74. PubMed ID: 15095224
[TBL] [Abstract][Full Text] [Related]
9. Factors associated with non-adherence to long-term highly active antiretroviral therapy: a 10 year follow-up analysis with correction for the bias induced by missing data.
Protopopescu C; Raffi F; Roux P; Reynes J; Dellamonica P; Spire B; Leport C; Carrieri MP;
J Antimicrob Chemother; 2009 Sep; 64(3):599-606. PubMed ID: 19602563
[TBL] [Abstract][Full Text] [Related]
10. 'Simply forgot' is the most frequently stated reason for missed doses of HAART irrespective of degree of adherence.
Barfod TS; Sørensen HT; Nielsen H; Rodkjaer L; Obel N
HIV Med; 2006 Jul; 7(5):285-90. PubMed ID: 16945072
[TBL] [Abstract][Full Text] [Related]
11. Validity of self-reported adherence among injection drug users.
Kerr T; Hogg RS; Yip B; Tyndall MW; Montaner J; Wood E
J Int Assoc Physicians AIDS Care (Chic); 2008; 7(4):157-9. PubMed ID: 18626123
[TBL] [Abstract][Full Text] [Related]
12. Survival of HIV-infected injection drug users (IDUs) in the highly active antiretroviral therapy era, relative to sex- and age-specific survival of HIV-uninfected IDUs.
Muga R; Langohr K; Tor J; Sanvisens A; Serra I; Rey-Joly C; Muñoz A
Clin Infect Dis; 2007 Aug; 45(3):370-6. PubMed ID: 17599317
[TBL] [Abstract][Full Text] [Related]
13. Adherence and plasma HIV RNA responses to highly active antiretroviral therapy among HIV-1 infected injection drug users.
Wood E; Montaner JS; Yip B; Tyndall MW; Schechter MT; O'Shaughnessy MV; Hogg RS
CMAJ; 2003 Sep; 169(7):656-61. PubMed ID: 14517122
[TBL] [Abstract][Full Text] [Related]
14. Mortality in HIV-seropositive versus -seronegative persons in the era of highly active antiretroviral therapy: implications for when to initiate therapy.
Wang C; Vlahov D; Galai N; Bareta J; Strathdee SA; Nelson KE; Sterling TR
J Infect Dis; 2004 Sep; 190(6):1046-54. PubMed ID: 15319852
[TBL] [Abstract][Full Text] [Related]
15. The impact of methadone or buprenorphine treatment and ongoing injection on highly active antiretroviral therapy (HAART) adherence: evidence from the MANIF2000 cohort study.
Roux P; Carrieri MP; Villes V; Dellamonica P; Poizot-Martin I; Ravaux I; Spire B;
Addiction; 2008 Nov; 103(11):1828-36. PubMed ID: 18778390
[TBL] [Abstract][Full Text] [Related]
16. The impact of incarceration upon adherence to HIV treatment among HIV-positive injection drug users: a qualitative study.
Small W; Wood E; Betteridge G; Montaner J; Kerr T
AIDS Care; 2009 Jun; 21(6):708-14. PubMed ID: 19806487
[TBL] [Abstract][Full Text] [Related]
17. Impact of HAART and injection drug use on life expectancy of two HIV-positive cohorts in British Columbia.
Lloyd-Smith E; Brodkin E; Wood E; Kerr T; Tyndall MW; Montaner JS; Hogg RS
AIDS; 2006 Feb; 20(3):445-50. PubMed ID: 16439879
[TBL] [Abstract][Full Text] [Related]
18. Received social support, self-efficacy, and finding benefits in disease as predictors of physical functioning and adherence to antiretroviral therapy.
Luszczynska A; Sarkar Y; Knoll N
Patient Educ Couns; 2007 Apr; 66(1):37-42. PubMed ID: 17097259
[TBL] [Abstract][Full Text] [Related]
19. Highly active antiretroviral therapy: physician experience and enhanced adherence to prescription refill.
Delgado J; Heath KV; Yip B; Marion S; Alfonso V; Montaner JS; O'Shaughnessy MV; Hogg RS
Antivir Ther; 2003 Oct; 8(5):471-8. PubMed ID: 14640395
[TBL] [Abstract][Full Text] [Related]
20. Adherence to antiretroviral therapy and CD4 T-cell count responses among HIV-infected injection drug users.
Wood E; Montaner JS; Yip B; Tyndall MW; Schechter MT; O'Shaughnessy MV; Hogg RS
Antivir Ther; 2004 Apr; 9(2):229-35. PubMed ID: 15134185
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
